Browsing Tag
nintedanib
4 posts
Cipla Limited (NSE: CIPLA) secures FDA approval for generic nintedanib capsules, entering a $3.8bn U.S. pulmonary fibrosis market
Cipla wins FDA approval for generic nintedanib capsules for IPF, targeting Boehringer Ingelheim's $3.76B Ofev market. Here's what the launch means for investors. Read more.
Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Avalyn Pharma advances AP02 into Phase 2 trials, testing inhaled drug delivery as a safer IPF strategy. Discover what this means for the fibrosis market.
Tvardi Therapeutics initiates REVERTIPF trial in idiopathic pulmonary fibrosis
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of STAT3 inhibitors, has reached a significant…
Glenmark Pharmaceuticals gets FDA approval for Nintedanib Capsules
Glenmark Pharmaceuticals Ltd said that it has secured tentative approval from the US Food and Drug Administration (FDA)…